Rasha A Hassan

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 10

Top Topics

Silver Nanoparticles

Molecular Docking

Renal Cell Carcinoma

Staphylococcus Aureus

Top Venues

Drug development research

Future medicinal chemistry

RSC medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Walid E Elgammal, Safaa S Shaban, Essam M Eliwa, Ahmed H Halawa, Shimaa M Abd El-Gilil, Rasha A Hassan, Amr M Abdou, Gameel Am Elhagali, Mam Abdel Reheim
Thiazolation of phenylthiosemicarbazone to access new thiazoles: anticancer activity and molecular docking. Future medicinal chemistry 16 (12) (2024)
Walid E Elgammal, Safaa S Shaban, Essam M Eliwa, Ahmed H Halawa, Shimaa M Abd El-Gilil, Rasha A Hassan, Amr M Abdou, Gameel Am Elhagali, Mam Abdel Reheim
Thiazolation of phenylthiosemicarbazone to access new thiazoles: anticancer activity and molecular docking. Future medicinal chemistry 16 (12) (2024)
Walid E Elgammal, Safaa S Shaban, Essam M Eliwa, Ahmed H Halawa, Shimaa M Abd El-Gilil, Rasha A Hassan, Amr M Abdou, Gameel Am Elhagali, Mam Abdel Reheim
Thiazolation of phenylthiosemicarbazone to access new thiazoles: anticancer activity and molecular docking. Future medicinal chemistry 16 (12) (2024)
Ahmed M Abdelhamed, Rasha A Hassan, Hanan H Kadry, Amira A Helwa
Novel pyrazolo[3,4- d ]pyrimidine derivatives: design, synthesis, anticancer evaluation, VEGFR-2 inhibition, and antiangiogenic activity. RSC medicinal chemistry 14 (12) (2023)
Safaa E Seif, Zeinab Mahmoud, Wagnat W Wardakhan, Amr M Abdou, Rasha A Hassan
Design and synthesis of novel hexahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as potential anticancer agents with antiangiogenic activity via VEGFR-2 inhibition, and down-regulation of PI3K/AKT/mTOR signaling pathway. Drug development research (2023)
Eman O Osman, Soha H Emam, Amr Sonousi, Mai M Kandil, Amr M Abdou, Rasha A Hassan
Design, synthesis, anticancer, and antibacterial evaluation of some quinazolinone-based derivatives as DHFR inhibitors. Drug development research (2023)
Ahmed M Abdelhamed, Rasha A Hassan, Hanan H Kadry, Amira A Helwa
Novel pyrazolo[3,4- d ]pyrimidine derivatives: design, synthesis, anticancer evaluation, VEGFR-2 inhibition, and antiangiogenic activity. RSC medicinal chemistry 14 (12) (2023)
Menna Tallah M Sayed, Peter A Halim, Afaf K El-Ansary, Rasha A Hassan
Design, synthesis, anticancer evaluation, and in silico studies of some thieno[2,3-d]pyrimidine derivatives as EGFR inhibitors. Drug development research (2023)
Sara Y Ewieda, Eman M Ahmed, Rasha A Hassan, Marwa S A Hassan
Pyridazine derivatives as selective COX-2 inhibitors: A review on recent updates. Drug development research (2023)
Soha H Emam, Rasha A Hassan, Eman O Osman, Mohammed I A Hamed, Amr M Abdou, Mai M Kandil, Eman Maher Elbaz, Demiana S Mikhail
Coumarin derivatives with potential anticancer and antibacterial activity: Design, synthesis, VEGFR-2 and DNA gyrase inhibition, and in silico studies. Drug development research (2023)